Moran Wealth Management LLC Purchases Shares of 40,552 Stoke Therapeutics, Inc. $STOK

Moran Wealth Management LLC purchased a new stake in Stoke Therapeutics, Inc. (NASDAQ:STOK) during the 1st quarter, Holdings Channel reports. The firm purchased 40,552 shares of the company’s stock, valued at approximately $1,320,000.

Several other institutional investors have also recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Stoke Therapeutics by 5.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,167 shares of the company’s stock valued at $162,000 after buying an additional 1,149 shares in the last quarter. Goldman Sachs Group Inc. increased its position in Stoke Therapeutics by 21.4% during the first quarter. Goldman Sachs Group Inc. now owns 1,662,039 shares of the company’s stock worth $11,053,000 after buying an additional 293,072 shares in the last quarter. Jane Street Group LLC increased its position in Stoke Therapeutics by 125.2% during the first quarter. Jane Street Group LLC now owns 26,978 shares of the company’s stock worth $179,000 after buying an additional 15,001 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Stoke Therapeutics by 26.6% in the second quarter. JPMorgan Chase & Co. now owns 25,655 shares of the company’s stock worth $291,000 after acquiring an additional 5,398 shares during the last quarter. Finally, Rhumbline Advisers raised its holdings in shares of Stoke Therapeutics by 33.9% in the second quarter. Rhumbline Advisers now owns 66,419 shares of the company’s stock worth $754,000 after acquiring an additional 16,820 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of analysts recently commented on STOK shares. Wedbush increased their price objective on Stoke Therapeutics from $36.00 to $38.00 and gave the company an “outperform” rating in a research note on Tuesday, March 17th. BTIG Research reissued a “buy” rating and issued a $39.00 target price on shares of Stoke Therapeutics in a research note on Monday, May 11th. Needham & Company LLC upped their target price on shares of Stoke Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, March 17th. Wall Street Zen cut shares of Stoke Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Finally, Canaccord Genuity Group boosted their price objective on shares of Stoke Therapeutics from $36.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, March 20th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Stoke Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $41.83.

Insider Activity

In other news, General Counsel Jonathan Allan sold 1,457 shares of the stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $29.95, for a total transaction of $43,637.15. Following the transaction, the general counsel directly owned 18,086 shares in the company, valued at $541,675.70. This represents a 7.46% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Barry Ticho sold 1,795 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $30.58, for a total transaction of $54,891.10. Following the completion of the sale, the insider directly owned 34,826 shares in the company, valued at $1,064,979.08. This represents a 4.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.50% of the stock is owned by insiders.

Stoke Therapeutics Stock Up 1.1%

Shares of STOK stock traded up $0.36 during mid-day trading on Tuesday, hitting $32.79. 32,139 shares of the company’s stock were exchanged, compared to its average volume of 745,717. The stock has a market cap of $2.04 billion, a price-to-earnings ratio of -11.63 and a beta of 1.17. Stoke Therapeutics, Inc. has a fifty-two week low of $11.66 and a fifty-two week high of $40.22. The stock has a 50-day simple moving average of $31.16 and a two-hundred day simple moving average of $32.35.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Thursday, May 7th. The company reported ($0.79) EPS for the quarter, beating the consensus estimate of ($0.80) by $0.01. Stoke Therapeutics had a negative return on equity of 48.84% and a negative net margin of 529.20%.The firm had revenue of $6.23 million during the quarter, compared to analyst estimates of $6.48 million. As a group, analysts anticipate that Stoke Therapeutics, Inc. will post -3.22 earnings per share for the current fiscal year.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.